Clinical trial
Effectiveness of KOS-862 in the Treatment of Lung Cancer
NCT00080509 · Bristol-Myers Squibb, Industry · Terminated
Key facts
| NCT number | NCT00080509 |
|---|---|
| Title | Effectiveness of KOS-862 in the Treatment of Lung Cancer |
| Official title | A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | KOS-862 |
| Enrollment | 85 |
| Start date | Dec 1, 2003 |
| Completion | Nov 1, 2004 |
| First posted | Apr 7, 2004 |
| Last update posted | Feb 3, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: